Laurion Capital Management LP Geron Corp Transaction History

Laurion Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.75 - $3.44 $2.92 Million - $5.73 Million	1,666,666 New	1,666,666 $5.5 Million
Q2 2023 Aug 14, 2023	SELL	$1.97 - $3.69 $48,720 - $91,257	-24,731 Reduced 10.72%	205,973 $661,000
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $493,706 - $784,393	230,704 New	230,704 $500,000

276

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.08B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.